OBJECTIVE: To explore changes in the phenotypic features of Sjögren's syndrome (SS), and in SS status among participants in the Sjögren's International Collaborative Clinical Alliance (SICCA) registry over a 2-3-year interval. METHODS: All participants in the SICCA registry who were found to have any objective measures of salivary hypofunction, dry eye, focal lymphocytic sialadenitis in minor salivary gland biopsy, or anti-SSA/SSB antibodies were recalled over a window of 2 to 3 years after their baseline examinations to repeat all clinical examinations and specimen collections to determine whether there was any change in phenotypic features and in SS status. RESULTS: As of September 15, 2013, a total of 3,514 participants had enrolled in SICCA, and among 3,310 eligible, 771 presented for a followup visit. Among participants found to have SS using the 2012 American College of Rheumatology (ACR) classification criteria, 93% again met the criteria after 2 to 3 years, and this proportion was 89% when using the 2016 ACR/European League Against Rheumatism (EULAR) criteria. Among those who did not meet ACR or ACR/EULAR criteria at baseline, 9% and 8%, respectively, had progressed and met them at followup. Those with hypergammaglobulinemia and hypocomplementemia at study entry were, respectively, 4 and 6 times more likely to progress to SS by ACR criteria than those without these characteristics (95% confidence interval 1.5-10.1 and 1.8-20.4, respectively). CONCLUSION: While there was stability over a 2-3-year period of both individual phenotypic features of SS and of SS status, hypergammaglobulinemia and hypocomplementemia at study entry were predictive of progression to SS.
OBJECTIVE: To explore changes in the phenotypic features of Sjögren's syndrome (SS), and in SS status among participants in the Sjögren's International Collaborative Clinical Alliance (SICCA) registry over a 2-3-year interval. METHODS: All participants in the SICCA registry who were found to have any objective measures of salivary hypofunction, dry eye, focal lymphocytic sialadenitis in minor salivary gland biopsy, or anti-SSA/SSB antibodies were recalled over a window of 2 to 3 years after their baseline examinations to repeat all clinical examinations and specimen collections to determine whether there was any change in phenotypic features and in SS status. RESULTS: As of September 15, 2013, a total of 3,514 participants had enrolled in SICCA, and among 3,310 eligible, 771 presented for a followup visit. Among participants found to have SS using the 2012 American College of Rheumatology (ACR) classification criteria, 93% again met the criteria after 2 to 3 years, and this proportion was 89% when using the 2016 ACR/European League Against Rheumatism (EULAR) criteria. Among those who did not meet ACR or ACR/EULAR criteria at baseline, 9% and 8%, respectively, had progressed and met them at followup. Those with hypergammaglobulinemia and hypocomplementemia at study entry were, respectively, 4 and 6 times more likely to progress to SS by ACR criteria than those without these characteristics (95% confidence interval 1.5-10.1 and 1.8-20.4, respectively). CONCLUSION: While there was stability over a 2-3-year period of both individual phenotypic features of SS and of SS status, hypergammaglobulinemia and hypocomplementemia at study entry were predictive of progression to SS.
Authors: Troy E Daniels; Darren Cox; Caroline H Shiboski; Morten Schiødt; Ava Wu; Hector Lanfranchi; Hisanori Umehara; Yan Zhao; Stephen Challacombe; Mi Y Lam; Yvonne De Souza; Julie Schiødt; Helena Holm; Patricia A M Bisio; Mariana S Gandolfo; Toshioki Sawaki; Mengtao Li; Wen Zhang; Beni Varghese-Jacob; Per Ibsen; Alicia Keszler; Nozomu Kurose; Takayuki Nojima; Edward Odell; Lindsey A Criswell; Richard Jordan; John S Greenspan Journal: Arthritis Rheum Date: 2011-07
Authors: C Vitali; S Bombardieri; H M Moutsopoulos; G Balestrieri; W Bencivelli; R M Bernstein; K B Bjerrum; S Braga; J Coll; S de Vita Journal: Arthritis Rheum Date: 1993-03
Authors: A A Kruize; R J Hené; A van der Heide; C Bodeutsch; P C de Wilde; O P van Bijsterveld; J de Jong; T E Feltkamp; L Kater; J W Bijlsma Journal: Arthritis Rheum Date: 1996-02
Authors: A Keszler; L I Adler; M S Gandolfo; P A Masquijo Bisio; A C Smith; C F Vollenweider; A M Heidenreich; G de Stefano; M V Kambo; D P Cox; M Narbaitz; H E Lanfranchi Journal: Oral Surg Oral Med Oral Pathol Oral Radiol Date: 2012-11-13
Authors: J A James; X R Kim-Howard; B F Bruner; M K Jonsson; M T McClain; M R Arbuckle; C Walker; G J Dennis; J T Merrill; J B Harley Journal: Lupus Date: 2007 Impact factor: 2.911
Authors: Vatinee Y Bunya; Mina Massaro-Giordano; Frederick B Vivino; Maureen G Maguire; Alan N Baer; John A Gonzales; Gui-Shuang Ying Journal: Cornea Date: 2019-12 Impact factor: 2.651
Authors: Sarah Pringle; Xiaoyan Wang; Gwenny M P J Verstappen; Janneke H Terpstra; Clarence K Zhang; Aiqing He; Vishal Patel; Rhiannon E Jones; Duncan M Baird; Fred K L Spijkervet; Arjan Vissink; Hendrika Bootsma; Robert P Coppes; Frans G M Kroese Journal: Arthritis Rheumatol Date: 2019-01 Impact factor: 10.995
Authors: Gwenny M Verstappen; Lu Gao; Sarah Pringle; Erlin A Haacke; Bert van der Vegt; Silvia C Liefers; Vishal Patel; Yanhua Hu; Sumanta Mukherjee; Julie Carman; Laurence C Menard; Frederik K L Spijkervet; Arjan Vissink; Hendrika Bootsma; Frans G M Kroese Journal: Front Immunol Date: 2021-07-06 Impact factor: 7.561
Authors: Vatinee Y Bunya; Maureen G Maguire; Esen K Akpek; Mina Massaro-Giordano; Sean Hennessy; Frederick B Vivino; John A Gonzales; Alan N Baer; Gui-Shuang Ying Journal: Cornea Date: 2021-02-01 Impact factor: 3.152